

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	11	14.1	78.0	(38.9-139.6)	Male	4	7.6	nc	(nc-nc)
Female	8	5.4	146.9	(63.2-289.4)	Female	5	6.3	79.0	(25.5-184.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	3.0	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	8	1.7	471.2	(202.9-928.5)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.4	nc	(nc-nc)	Male	8	7.4	107.8	(46.4-212.4)
Female	64	58.6	109.1	(84.0-139.4)	Female	1	6.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	2.8	nc	(nc-nc)	Male	7	5.7	121.8	(48.8-250.9)
Colon / Rectum					Female	2	2.8	nc	(nc-nc)
Male	22	22.0	100.2	(62.8-151.8)	Ovary				
Female	34	22.2	152.8	(105.8-213.6)	Female	8	6.0	133.8	(57.6-263.6)
Esophagus					Pancreas				
Male	3	3.5	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	1.3	nc	(nc-nc)	Male	57	58.9	96.8	(73.3-125.4)
Female	0	1.1	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	4	3.7	nc	(nc-nc)
Male	8	5.9	136.0	(58.5-267.9)	Female	1	2.4	nc	(nc-nc)
Female	7	3.9	177.9	(71.3-366.6)	Testis				
Larynx					Male	3	2.4	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)					

Leukemia	Female	1	0.7	nc	(nc-nc)
	Male	10	4.5	219.9	(105.3-404.4)
	Female	3	3.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	1	2.7	nc	(nc-nc)
	Female	1	1.1	nc	(nc-nc)
Lung and Bronchus	Male	39	27.8	140.3	(99.7-191.8)
	Female	30	25.1	119.5	(80.6-170.7)

Thyroid

	Male	1	1.5	nc	(nc-nc)
	Female	6	5.0	120.9	(44.1-263.2)

Uteri Corpus and Uterus, NOS

	Female	12	11.4	105.1	(54.2-183.6)
--	--------	----	------	-------	--------------

All Sites / Types

	Male	201	194.0	103.6	(89.8-119.0)
	Female	220	189.4	116.2	(101.3-132.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

12 Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	14	16.1	86.9	(47.4-145.8)
Female	7	5.7	122.9	(49.2-253.2)
Brain and Other Nervous System				
Male	3	3.9	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)
Breast				
Male	1	0.5	nc	(nc-nc)
Female	101	75.0	134.7	(109.7-163.7)
Cervix Uteri				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	8	9.7	82.3	(35.5-162.3)
Female	11	8.1	136.0	(67.8-243.3)
Multiple Myeloma				
Male	1	2.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	10	9.2	108.2	(51.8-198.9)
Female	6	7.7	78.2	(28.5-170.2)
Oral Cavity & Pharynx				

Colon / Rectum	Female	2	3.9	nc	(nc-nc)	Male	3	7.7	nc	(nc-nc)
	Male	29	25.7	112.9	(75.6-162.2)	Female	4	3.4	nc	(nc-nc)
Esophagus	Female	14	22.5	62.2	(34.0-104.4)	Female	6	7.4	81.2	(29.7-176.8)
	Male	1	4.4	nc	(nc-nc)	Male	8	4.9	164.3	(70.8-323.9)
Hodgkin Lymphoma	Female	1	1.1	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
	Male	1	1.7	nc	(nc-nc)	Male	73	72.2	101.1	(79.3-127.2)
Kidney & Renal Pelvis	Female	2	1.4	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
	Male	8	7.5	106.1	(45.7-209.1)	Female	1	2.3	nc	(nc-nc)
Larynx	Female	3	4.6	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
	Male	2	3.3	nc	(nc-nc)	Male	5	2.1	237.3	(76.5-553.7)
Leukemia	Female	0	0.8	nc	(nc-nc)	Female	4	6.9	nc	(nc-nc)
	Male	7	5.6	125.3	(50.2-258.3)	Female	17	14.5	117.3	(68.3-187.8)
Liver and Intrahepatic Bile Ducts	Female	2	4.4	nc	(nc-nc)	Male	206	235.9	87.3	(75.8-100.1)
	Male	2	3.5	nc	(nc-nc)	Female	225	222.5	101.1	(88.3-115.2)
Lung and Bronchus	Female	2	1.1	nc	(nc-nc)	Male	206	235.9	87.3	(75.8-100.1)
	Male	13	32.9	39.5	(21.0-67.5)	Female	225	222.5	101.1	(88.3-115.2)
	Female	25	27.6	90.6	(58.6-133.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

13
Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	13	12.5	103.9	(55.3-177.7)	Male	6	6.4	94.0	(34.3-204.7)
Female	3	4.4	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	2.4	211.2	(68.1-492.8)	Male	2	1.8	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
Female	51	47.0	108.5	(80.7-142.6)	Female	3	5.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	2.1	nc	(nc-nc)	Male	2	4.9	nc	(nc-nc)
Colon / Rectum					Female	1	2.2	nc	(nc-nc)
Male	22	19.4	113.6	(71.2-172.1)	Ovary				
Female	13	17.3	74.9	(39.9-128.2)	Female	4	4.7	nc	(nc-nc)
Esophagus					Pancreas				
Male	6	3.1	193.9	(70.8-422.0)	Male	7	3.6	193.6	(77.5-398.8)
Female	1	0.9	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	2	1.0	nc	(nc-nc)	Male	42	52.7	79.7	(57.4-107.7)
Female	0	0.8	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	2	3.3	nc	(nc-nc)
Male	8	5.1	157.4	(67.8-310.2)					

Larynx	Female	4	3.2	nc	(nc-nc)	Testis	Female	4	1.8	nc	(nc-nc)
	Male	5	2.3	216.1	(69.6-504.3)		Male	2	1.6	nc	(nc-nc)
Leukemia	Female	0	0.6	nc	(nc-nc)	Thyroid					
	Male	5	3.8	132.1	(42.6-308.3)		Male	0	1.2	nc	(nc-nc)
	Female	1	2.9	nc	(nc-nc)		Female	3	3.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	2	2.4	nc	(nc-nc)						
	Female	2	0.8	nc	(nc-nc)		Female	3	9.4	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	31	24.9	124.3	(84.4-176.5)		Male	174	169.5	102.6	(87.9-119.1)
	Female	19	20.8	91.4	(55.0-142.8)		Female	129	150.3	85.8	(71.7-102.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

14
Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	16	12.5	127.8	(73.0-207.6)	Male	2	5.8	nc	(nc-nc)
Female	0	5.1	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	2.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Cervix Uteri	Male	0	0.4	nc	(nc-nc)
	Female	38	46.0	82.6	(58.4-113.3)
Colon / Rectum	Female	1	1.9	nc	(nc-nc)
	Male	21	19.0	110.5	(68.4-169.0)
Esophagus	Female	24	21.2	113.5	(72.7-168.8)
	Male	3	2.9	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	1.0	nc	(nc-nc)
	Male	1	0.8	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.7	nc	(nc-nc)
	Male	10	4.6	217.2	(104.0-399.4)
Larynx	Female	2	3.4	nc	(nc-nc)
	Male	4	2.1	nc	(nc-nc)
Leukemia	Female	0	0.6	nc	(nc-nc)
	Male	3	3.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	3	3.3	nc	(nc-nc)
	Male	3	2.1	nc	(nc-nc)
Lung and Bronchus	Female	1	1.0	nc	(nc-nc)
	Male	22	24.1	91.4	(57.2-138.3)
	Female	22	22.7	96.7	(60.6-146.5)

Oral Cavity & Pharynx	Male	9	5.8	154.5	(70.5-293.4)
	Female	3	6.0	nc	(nc-nc)
Ovary	Male	5	4.2	117.8	(37.9-274.8)
	Female	3	2.3	nc	(nc-nc)
Pancreas	Female	4	4.8	nc	(nc-nc)
	Male	5	3.5	142.4	(45.9-332.2)
Prostate	Female	3	4.4	nc	(nc-nc)
	Male	43	48.4	88.8	(64.3-119.6)
Stomach	Male	1	3.2	nc	(nc-nc)
	Female	1	2.2	nc	(nc-nc)
Testis	Male	1	1.3	nc	(nc-nc)
	Female	3	3.1	nc	(nc-nc)
Thyroid	Male	0	1.0	nc	(nc-nc)
	Female	3	3.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	9	9.1	98.6	(45.0-187.2)
	Male	157	159.7	98.3	(83.5-115.0)
All Sites / Types	Female	141	159.4	88.5	(74.5-104.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

15

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	37	33.1	111.7	(78.7-154.0)	Male	16	16.6	96.2	(54.9-156.2)
Female	12	13.6	88.0	(45.4-153.8)	Female	11	14.0	78.5	(39.1-140.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	6.2	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
Female	6	5.6	106.4	(38.8-231.6)	Female	5	4.2	118.3	(38.1-276.1)
Breast					Non-Hodgkin Lymphoma				
Male	0	1.0	nc	(nc-nc)	Male	15	16.5	91.1	(51.0-150.3)
Female	128	134.8	95.0	(79.2-112.9)	Female	18	16.5	108.9	(64.5-172.1)
Cervix Uteri					Oral Cavity & Pharynx				
Female	5	6.0	83.0	(26.7-193.7)	Male	15	12.5	120.2	(67.2-198.3)
Colon / Rectum					Female	5	6.6	75.6	(24.4-176.4)
Male	54	51.0	105.9	(79.6-138.2)	Ovary				
Female	60	56.6	106.0	(80.9-136.4)	Female	14	13.9	100.8	(55.1-169.1)
Esophagus					Pancreas				
Male	4	7.9	nc	(nc-nc)	Male	3	9.5	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	11	11.8	93.5	(46.6-167.3)
Hodgkin Lymphoma					Prostate				
Male	3	2.6	nc	(nc-nc)	Male	118	132.0	89.4	(74.0-107.0)
Female	5	2.3	219.2	(70.6-511.5)					

Kidney & Renal Pelvis					Stomach				
Male	15	13.0	115.3	(64.5-190.2)	Male	8	8.7	91.7	(39.5-180.8)
Female	8	9.3	85.7	(36.9-168.9)	Female	6	6.1	98.2	(35.9-213.8)
Larynx					Testis				
Male	3	5.9	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)					
Leukemia					Thyroid				
Male	7	10.0	69.9	(28.0-144.0)	Male	4	3.1	nc	(nc-nc)
Female	14	9.2	151.8	(82.9-254.6)	Female	11	10.1	109.0	(54.3-195.1)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	7	6.1	115.5	(46.3-238.0)					
Female	0	2.6	nc	(nc-nc)	Female	27	26.4	102.4	(67.5-149.0)
Lung and Bronchus					All Sites / Types				
Male	71	64.2	110.6	(86.3-139.5)	Male	425	437.7	97.1	(88.1-106.8)
Female	47	60.8	77.3	(56.8-102.8)	Female	427	449.0	95.1	(86.3-104.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

16
Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.8	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)

Breast	Female	0	0.1	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Cervix Uteri	Female	2	2.2	nc	(nc-nc)
Colon / Rectum	Female	1	0.1	nc	(nc-nc)
	Male	1	1.2	nc	(nc-nc)
Esophagus	Female	1	0.8	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.0	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Kidney & Renal Pelvis	Male	0	0.3	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Larynx	Male	0	0.1	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)
Leukemia	Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.1	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)
Lung and Bronchus					

Non-Hodgkin Lymphoma	Female	0	0.1	nc	(nc-nc)
	Male	1	0.4	nc	(nc-nc)
Oral Cavity & Pharynx	Female	0	0.2	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Ovary	Female	0	0.1	nc	(nc-nc)
Pancreas	Female	1	0.2	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Prostate	Female	0	0.2	nc	(nc-nc)
	Male	3	3.2	nc	(nc-nc)
Stomach	Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Testis	Male	0	0.0	nc	(nc-nc)
Thyroid	Male	0	0.1	nc	(nc-nc)
	Female	1	0.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					
	Female	0	0.5	nc	(nc-nc)
All Sites / Types					

Male	1	1.5	nc	(nc-nc)	Male	10	10.2	97.7	(46.8-179.7)
Female	0	1.0	nc	(nc-nc)	Female	6	6.9	86.4	(31.5-188.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

17
Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	16	14.2	113.0	(64.6-183.6)	Male	9	7.8	114.8	(52.4-217.9)
Female	7	5.8	121.7	(48.8-250.8)	Female	9	6.9	131.1	(59.8-248.9)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	3.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	6	1.8	335.0	(122.3-729.3)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	6	7.6	78.7	(28.7-171.2)
Female	54	62.6	86.3	(64.8-112.6)	Female	10	7.3	136.9	(65.5-251.8)
Cervix Uteri					Oral Cavity & Pharynx				
Female	5	3.1	159.5	(51.4-372.2)	Male	6	5.8	102.6	(37.5-223.3)
Colon / Rectum					Female	3	3.0	nc	(nc-nc)
Male	23	22.1	104.1	(66.0-156.2)	Ovary				
Female	31	23.5	132.0	(89.6-187.3)	Female	4	6.4	nc	(nc-nc)
Esophagus					Pancreas				
Male	6	3.5	169.5	(61.9-368.8)	Male	3	4.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	7	4.9	143.8	(57.6-296.4)

Hodgkin Lymphoma					Prostate				
Male	2	1.4	nc	(nc-nc)	Male	63	58.8	107.2	(82.4-137.2)
Female	0	1.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	12	6.0	200.2	(103.3-349.7)	Male	4	3.8	nc	(nc-nc)
Female	6	4.2	144.0	(52.6-313.4)	Female	2	2.5	nc	(nc-nc)
Larynx					Testis				
Male	1	2.6	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)					
Leukemia					Thyroid				
Male	7	4.7	149.8	(60.0-308.6)	Male	2	1.6	nc	(nc-nc)
Female	5	4.2	119.4	(38.5-278.8)	Female	5	5.5	90.8	(29.3-211.9)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	2.8	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)	Female	14	12.0	117.0	(63.9-196.3)
Lung and Bronchus					All Sites / Types				
Male	31	28.0	110.7	(75.2-157.2)	Male	215	196.1	109.7	(95.5-125.3)
Female	35	26.2	133.5	(93.0-185.6)	Female	222	201.3	110.3	(96.3-125.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

18
Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	12	17.5	68.7	(35.5-120.1)	Male	7	10.5	66.9	(26.8-137.9)

Brain and Other Nervous System	Female	5	7.1	70.3	(22.6-164.0)
	Male	4	4.8	nc	(nc-nc)
Breast	Female	1	4.1	nc	(nc-nc)
	Male	1	0.5	nc	(nc-nc)
	Female	79	78.9	100.1	(79.2-124.8)
Cervix Uteri					
	Female	3	4.2	nc	(nc-nc)
Colon / Rectum					
	Male	28	27.3	102.6	(68.2-148.3)
	Female	20	28.9	69.3	(42.3-107.0)
Esophagus					
	Male	4	4.3	nc	(nc-nc)
	Female	0	1.4	nc	(nc-nc)
Hodgkin Lymphoma					
	Male	3	3.9	nc	(nc-nc)
	Female	4	3.6	nc	(nc-nc)
Kidney & Renal Pelvis					
	Male	3	7.4	nc	(nc-nc)
	Female	4	5.3	nc	(nc-nc)
Larynx					
	Male	2	3.2	nc	(nc-nc)
	Female	0	0.9	nc	(nc-nc)
Leukemia					
	Male	5	6.6	75.3	(24.3-175.7)
	Female	4	5.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					

Multiple Myeloma	Female	8	10.2	78.4	(33.7-154.4)
	Male	2	2.5	nc	(nc-nc)
Non-Hodgkin Lymphoma	Female	4	2.2	nc	(nc-nc)
	Male	10	10.8	92.3	(44.2-169.8)
	Female	9	9.7	92.7	(42.3-176.1)
Oral Cavity & Pharynx					
	Male	4	7.3	nc	(nc-nc)
	Female	4	4.0	nc	(nc-nc)
Ovary					
	Female	6	8.5	70.6	(25.8-153.7)
Pancreas					
	Male	8	5.1	157.1	(67.6-309.5)
	Female	3	5.9	nc	(nc-nc)
Prostate					
	Male	83	71.6	115.8	(92.3-143.6)
Stomach					
	Male	3	4.7	nc	(nc-nc)
	Female	1	3.1	nc	(nc-nc)
Testis					
	Male	3	6.5	nc	(nc-nc)
Thyroid					
	Male	0	2.6	nc	(nc-nc)
	Female	3	9.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					

Male	2	3.4	nc	(nc-nc)					
Female	2	1.4	nc	(nc-nc)	Female	16	15.4	104.1	(59.5-169.1)
Lung and Bronchus					All Sites / Types				
Male	13	34.2	38.0	(20.2-65.0)	Male	210	252.2	83.3	(72.4-95.3)
Female	16	32.4	49.4	(28.2-80.1)	Female	208	261.5	79.5	(69.1-91.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

19

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	38	30.8	123.3	(87.2-169.2)	Male	14	16.9	83.1	(45.4-139.4)
Female	11	11.7	93.8	(46.7-167.8)	Female	15	13.9	107.7	(60.2-177.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	6.5	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	3	5.6	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	3	1.0	nc	(nc-nc)	Male	11	16.3	67.4	(33.6-120.6)
Female	146	134.7	108.4	(91.5-127.4)	Female	18	14.9	121.0	(71.6-191.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	5	6.3	79.3	(25.6-185.1)	Male	9	13.3	67.5	(30.8-128.1)
					Female	7	6.3	111.8	(44.8-230.4)
Colon / Rectum					Ovary				
Male	40	48.4	82.7	(59.1-112.6)					
Female	45	47.4	95.0	(69.3-127.1)	Female	8	13.5	59.2	(25.5-116.7)

Esophagus					Pancreas				
Male	6	8.0	75.0	(27.4-163.3)	Male	13	9.1	142.6	(75.8-243.8)
Female	2	2.3	nc	(nc-nc)	Female	9	9.7	92.3	(42.1-175.3)
Hodgkin Lymphoma					Prostate				
Male	3	2.7	nc	(nc-nc)	Male	140	134.4	104.2	(87.6-122.9)
Female	3	2.3	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	13	13.4	96.9	(51.6-165.8)	Male	5	8.2	61.0	(19.7-142.4)
Female	9	8.7	103.1	(47.1-195.8)	Female	3	5.0	nc	(nc-nc)
Larynx					Testis				
Male	2	6.0	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)					
Leukemia					Thyroid				
Male	8	9.9	80.8	(34.8-159.2)	Male	3	3.3	nc	(nc-nc)
Female	7	8.4	83.7	(33.5-172.4)	Female	19	10.8	175.6	(105.7-274.2)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	6.2	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)	Female	29	26.4	109.9	(73.6-157.8)
Lung and Bronchus					All Sites / Types				
Male	39	62.1	62.8	(44.6-85.8)	Male	380	432.8	87.8	(79.2-97.1)
Female	41	54.9	74.7	(53.6-101.3)	Female	409	419.8	97.4	(88.2-107.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	1	0.5	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Larynx					Testis				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
Leukemia					Thyroid				

Male	3	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	0.1	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	1	0.7	nc	(nc-nc)	Male	10	4.4	229.0	(109.7-421.2)
Female	0	0.5	nc	(nc-nc)	Female	1	4.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

21 Arlington									
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	43	48.8	88.1	(63.7-118.6)	Male	27	24.4	110.7	(72.9-161.1)
Female	26	21.5	121.2	(79.1-177.5)	Female	21	22.2	94.6	(58.5-144.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	11	9.0	122.6	(61.1-219.4)	Male	8	6.7	118.6	(51.1-233.7)
Female	11	8.8	125.5	(62.5-224.5)	Female	9	6.7	134.2	(61.2-254.8)
Breast					Non-Hodgkin Lymphoma				
Male	2	1.5	nc	(nc-nc)	Male	30	24.1	124.4	(83.9-177.6)
Female	214	209.1	102.3	(89.1-117.0)	Female	29	26.2	110.8	(74.2-159.2)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	24	17.8	134.7	(86.3-200.5)
Female	8	9.6	83.0	(35.7-163.6)	Female	10	10.4	96.6	(46.3-177.7)

Colon / Rectum					Ovary				
Male	68	75.0	90.7	(70.4-115.0)					
Female	83	88.8	93.4	(74.4-115.8)	Female	16	21.6	74.1	(42.3-120.3)
Esophagus					Pancreas				
Male	7	11.6	60.4	(24.2-124.4)	Male	6	13.9	43.3	(15.8-94.2)
Female	6	4.3	138.7	(50.7-301.9)	Female	20	18.5	108.0	(66.0-166.8)
Hodgkin Lymphoma					Prostate				
Male	3	3.9	nc	(nc-nc)	Male	187	195.4	95.7	(82.5-110.4)
Female	5	3.6	137.1	(44.2-319.9)					
Kidney & Renal Pelvis					Stomach				
Male	21	18.9	111.0	(68.7-169.7)	Male	10	12.7	78.5	(37.6-144.4)
Female	18	14.7	122.4	(72.5-193.5)	Female	5	9.5	52.4	(16.9-122.4)
Larynx					Testis				
Male	6	8.5	70.3	(25.7-153.0)	Male	6	7.2	83.5	(30.5-181.6)
Female	4	2.6	nc	(nc-nc)					
Leukemia					Thyroid				
Male	15	14.6	102.5	(57.3-169.1)	Male	3	4.6	nc	(nc-nc)
Female	15	14.4	104.0	(58.2-171.5)	Female	24	16.2	148.1	(94.9-220.4)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	6	8.8	68.2	(24.9-148.4)					
Female	5	4.1	120.8	(38.9-282.0)	Female	33	40.8	80.8	(55.6-113.5)
Lung and Bronchus					All Sites / Types				
Male	68	95.2	71.5	(55.5-90.6)	Male	587	644.9	91.0	(83.8-98.7)
Female	90	96.6	93.1	(74.9-114.5)	Female	705	703.4	100.2	(93.0-107.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	4.7	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	22	20.2	109.1	(68.3-165.2)	Female	3	2.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	1.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
					Female	0	0.9	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	9	7.5	120.1	(54.8-228.0)					
Female	12	6.2	194.0	(100.1-338.8)	Female	2	2.0	nc	(nc-nc)
Esophagus					Pancreas				
Male	5	1.3	397.2	(128.0-927.0)	Male	5	1.4	352.2	(113.5-821.9)
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.5	nc	(nc-nc)	Male	14	20.7	67.5	(36.9-113.3)
Female	0	0.4	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	4	2.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Larynx					Testis				

Male	1	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
Leukemia					Thyroid				
Male	3	1.6	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	1.0	nc	(nc-nc)					
Female	1	0.3	nc	(nc-nc)	Female	1	3.8	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	5	9.6	52.1	(16.8-121.5)	Male	62	68.4	90.6	(69.5-116.2)
Female	6	7.5	79.5	(29.0-173.1)	Female	67	60.3	111.1	(86.1-141.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

23
Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	2.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	9	10.3	87.0	(39.7-165.2)	Female	0	1.1	nc	(nc-nc)

Cervix Uteri						Oral Cavity & Pharynx				
	Female	0	0.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Colon / Rectum						Female	1	0.5	nc	(nc-nc)
	Male	2	3.9	nc	(nc-nc)	Ovary				
	Female	6	3.4	175.8	(64.2-382.7)	Female	1	1.0	nc	(nc-nc)
Esophagus						Pancreas				
	Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.3	nc	(nc-nc)	Male	15	10.8	138.3	(77.3-228.1)
	Female	1	0.2	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis						Male	0	0.6	nc	(nc-nc)
	Male	2	1.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
	Female	0	0.7	nc	(nc-nc)	Testis				
Larynx						Male	1	0.4	nc	(nc-nc)
	Male	0	0.5	nc	(nc-nc)	Thyroid				
	Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Leukemia						Female	0	0.9	nc	(nc-nc)
	Male	0	0.8	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
	Female	4	0.6	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						All Sites / Types				
	Male	1	0.5	nc	(nc-nc)	Male	35	35.2	99.4	(69.2-138.3)
	Female	0	0.2	nc	(nc-nc)	Female	35	31.7	110.4	(76.9-153.5)
Lung and Bronchus										
	Male	5	5.0	99.9	(32.2-233.2)					
	Female	6	4.1	146.5	(53.5-318.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

24

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	2.0	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	7	7.9	88.5	(35.5-182.4)	Female	0	0.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	2	3.1	nc	(nc-nc)					
Female	3	2.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.2	nc	(nc-nc)	Male	11	8.1	135.6	(67.6-242.7)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	2	0.8	nc	(nc-nc)	Testis	Male	0	0.5	nc	(nc-nc)
	Female	1	0.5	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
	Male	1	0.4	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
	Female	1	0.1	nc	(nc-nc)						
Leukemia	Male	0	0.6	nc	(nc-nc)	Thyroid	Male	1	0.2	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)		Female	0	0.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.4	nc	(nc-nc)	Uteri Corpus and Uterus, NOS					
	Female	0	0.1	nc	(nc-nc)		Female	1	1.5	nc	(nc-nc)
Lung and Bronchus	Male	6	3.9	153.2	(56.0-333.5)	All Sites / Types	Male	32	27.2	117.8	(80.6-166.3)
	Female	1	3.0	nc	(nc-nc)		Female	21	23.6	88.8	(54.9-135.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

25

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	13	12.2	106.5	(56.7-182.2)	Male	11	7.1	156.0	(77.8-279.1)
Female	3	4.4	nc	(nc-nc)	Female	8	6.0	133.5	(57.5-263.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	2.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
	Male	0	0.4	nc	(nc-nc)		Male	6	6.8	88.6 (32.4-192.9)
	Female	52	54.4	95.6	(71.4-125.4)		Female	4	5.9	nc (nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
	Female	2	2.8	nc	(nc-nc)		Male	9	5.4	167.8 (76.6-318.6)
							Female	0	2.5	nc (nc-nc)
Colon / Rectum						Ovary				
	Male	25	19.2	130.1	(84.2-192.1)					
	Female	27	17.1	157.5	(103.8-229.2)		Female	8	5.4	148.3 (63.9-292.2)
Esophagus						Pancreas				
	Male	3	3.2	nc	(nc-nc)		Male	3	3.6	nc (nc-nc)
	Female	0	0.8	nc	(nc-nc)		Female	5	3.5	142.2 (45.8-331.8)
Hodgkin Lymphoma						Prostate				
	Male	0	1.3	nc	(nc-nc)		Male	39	52.8	73.9 (52.6-101.0)
	Female	2	1.1	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	2	5.4	nc	(nc-nc)		Male	3	3.3	nc (nc-nc)
	Female	4	3.4	nc	(nc-nc)		Female	2	1.8	nc (nc-nc)
Larynx						Testis				
	Male	2	2.4	nc	(nc-nc)		Male	1	2.4	nc (nc-nc)
	Female	2	0.6	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	4	4.1	nc	(nc-nc)		Male	0	1.5	nc (nc-nc)
	Female	1	3.3	nc	(nc-nc)		Female	5	5.1	98.0 (31.6-228.6)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	1	2.5	nc	(nc-nc)					
	Female	0	0.8	nc	(nc-nc)		Female	11	10.5	104.4 (52.1-186.9)
Lung and Bronchus						All Sites / Types				
	Male	13	24.7	52.7	(28.0-90.2)		Male	145	173.9	83.4 (70.4-98.1)

Female 19 21.3 89.3 (53.8-139.5)

Female 169 165.4 102.2 (87.4-118.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

26

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	10	13.6	73.3	(35.1-134.8)	Male	7	6.5	107.1	(42.9-220.6)
Female	2	5.4	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.4	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.4	nc	(nc-nc)	Male	6	6.6	91.2	(33.3-198.4)
Female	41	50.7	80.9	(58.1-109.8)	Female	6	6.5	92.6	(33.8-201.6)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	2.2	nc	(nc-nc)	Male	6	4.8	124.9	(45.6-271.9)
Colon / Rectum					Female	2	2.5	nc	(nc-nc)
Male	29	20.8	139.3	(93.3-200.0)	Ovary				
Female	20	22.5	88.9	(54.2-137.2)	Female	7	5.3	132.8	(53.2-273.5)
Esophagus					Pancreas				
Male	1	3.2	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	8	4.7	170.7	(73.5-336.4)
Hodgkin Lymphoma					Prostate				

Male	2	1.0	nc	(nc-nc)	Male	51	52.2	97.7	(72.7-128.5)
Female	0	0.9	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	5	5.1	98.3	(31.7-229.4)	Male	6	3.6	167.1	(61.0-363.7)
Female	3	3.6	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Larynx					Testis				
Male	1	2.3	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)					
Leukemia					Thyroid				
Male	5	4.1	122.8	(39.6-286.7)	Male	3	1.2	nc	(nc-nc)
Female	5	3.6	137.6	(44.3-321.1)	Female	1	3.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	5	2.4	210.5	(67.8-491.3)					
Female	0	1.0	nc	(nc-nc)	Female	10	9.9	101.4	(48.6-186.5)
Lung and Bronchus					All Sites / Types				
Male	29	25.9	111.9	(74.9-160.8)	Male	188	175.3	107.2	(92.5-123.7)
Female	19	23.9	79.7	(47.9-124.4)	Female	150	173.0	86.7	(73.4-101.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

27
Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	32	38.7	82.7	(56.5-116.7)	Male	27	20.7	130.6	(86.0-190.0)
Female	19	15.6	121.6	(73.2-189.9)	Female	21	17.7	118.8	(73.5-181.6)

Brain and Other Nervous System						Multiple Myeloma				
Male	10	8.1	122.8	(58.8-225.8)		Male	7	5.5	128.4	(51.4-264.6)
Female	6	7.2	83.9	(30.6-182.6)		Female	5	4.9	102.8	(33.1-239.9)
Breast						Non-Hodgkin Lymphoma				
Male	2	1.2	nc	(nc-nc)		Male	15	20.3	74.0	(41.4-122.0)
Female	164	162.3	101.1	(86.2-117.8)		Female	18	19.6	91.7	(54.3-144.9)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	17	15.3	111.0	(64.6-177.7)
Female	6	7.9	76.1	(27.8-165.6)		Female	14	7.9	177.6	(97.0-298.0)
Colon / Rectum						Ovary				
Male	47	60.1	78.3	(57.5-104.1)						
Female	64	64.0	100.0	(77.0-127.8)		Female	15	16.7	90.0	(50.4-148.5)
Esophagus						Pancreas				
Male	13	9.5	136.4	(72.5-233.2)		Male	7	11.2	62.6	(25.1-129.0)
Female	2	3.1	nc	(nc-nc)		Female	14	13.3	105.5	(57.6-177.1)
Hodgkin Lymphoma						Prostate				
Male	8	3.7	213.8	(92.0-421.2)		Male	149	160.1	93.1	(78.7-109.3)
Female	3	3.2	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	18	15.9	112.9	(66.8-178.4)		Male	10	10.2	98.2	(47.0-180.5)
Female	10	11.1	89.9	(43.1-165.4)		Female	6	6.8	88.0	(32.1-191.5)
Larynx						Testis				
Male	9	7.1	126.2	(57.6-239.6)		Male	8	6.9	115.5	(49.7-227.7)
Female	2	2.0	nc	(nc-nc)						
Leukemia						Thyroid				
Male	10	12.5	79.9	(38.3-147.0)		Male	8	4.2	190.2	(81.9-374.8)
Female	10	11.1	89.9	(43.0-165.4)		Female	19	13.8	138.1	(83.1-215.7)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	11	7.4	149.0	(74.3-266.7)						

Female	3	3.0	nc	(nc-nc)	Female	34	31.6	107.4	(74.4-150.1)
Lung and Bronchus					All Sites / Types				
Male	89	76.5	116.3	(93.4-143.1)	Male	536	529.9	101.2	(92.8-110.1)
Female	70	71.4	98.0	(76.4-123.8)	Female	540	533.3	101.3	(92.9-110.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

28 Auburn Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	21	20.9	100.5	(62.2-153.7)	Male	5	10.1	49.7	(16.0-115.9)
Female	9	7.8	115.3	(52.6-218.8)	Female	3	7.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	3.7	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)	Male	12	10.0	119.7	(61.8-209.1)
Female	60	77.3	77.6	(59.2-99.9)	Female	12	9.5	126.4	(65.2-220.7)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	3.4	nc	(nc-nc)	Male	6	7.5	80.0	(29.2-174.0)
Colon / Rectum					Female	3	3.8	nc	(nc-nc)
Male	28	32.0	87.6	(58.2-126.6)	Ovary				
Female	28	32.0	87.4	(58.1-126.3)	Female	6	7.9	75.5	(27.6-164.4)
Esophagus					Pancreas				

Hodgkin Lymphoma	Male	8	4.9	162.0	(69.8-319.3)	Prostate	Male	3	5.9	nc	(nc-nc)
	Female	0	1.6	nc	(nc-nc)		Female	9	6.7	134.8	(61.5-255.9)
Kidney & Renal Pelvis	Male	2	1.4	nc	(nc-nc)	Stomach	Male	80	83.1	96.2	(76.3-119.8)
	Female	0	1.2	nc	(nc-nc)		Female	4	3.4	nc	(nc-nc)
Larynx	Male	2	3.6	nc	(nc-nc)	Testis	Male	6	2.4	254.1	(92.8-553.1)
	Female	0	1.0	nc	(nc-nc)		Female	8	5.5	144.7	(62.3-285.1)
Leukemia	Male	5	6.1	81.7	(26.3-190.6)	Thyroid	Male	2	1.8	nc	(nc-nc)
	Female	5	5.2	96.1	(31.0-224.2)		Female	23	15.3	149.9	(95.0-224.9)
Liver and Intrahepatic Bile Ducts	Male	5	3.7	135.0	(43.5-315.1)	All Sites / Types	Male	251	272.5	92.1	(81.1-104.3)
	Female	0	1.5	nc	(nc-nc)		Female	233	257.1	90.6	(79.4-103.1)
Lung and Bronchus	Male	37	40.6	91.1	(64.2-125.6)						
	Female	37	35.8	103.2	(72.7-142.3)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	8	5.5	144.9	(62.4-285.5)		Male	2	2.7	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)		Female	2	2.2	nc	(nc-nc)
Brain and Other Nervous System						Multiple Myeloma				
Male	2	1.0	nc	(nc-nc)		Male	3	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)		Female	2	0.7	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)		Male	2	2.7	nc	(nc-nc)
Female	20	21.1	94.7	(57.8-146.3)		Female	3	2.5	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
Female	4	0.9	nc	(nc-nc)		Male	1	2.0	nc	(nc-nc)
Colon / Rectum						Female	2	1.0	nc	(nc-nc)
Male	11	8.5	129.8	(64.7-232.3)		Ovary				
Female	13	8.2	157.9	(84.0-270.0)		Female	1	2.1	nc	(nc-nc)
Esophagus						Pancreas				
Male	2	1.3	nc	(nc-nc)		Male	2	1.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)		Female	2	1.7	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.4	nc	(nc-nc)		Male	27	22.7	118.8	(78.3-172.8)
Female	1	0.4	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	2	1.4	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)		Testis				
Larynx						Male	0	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)		Thyroid				
Female	1	0.3	nc	(nc-nc)		Male	1	0.5	nc	(nc-nc)
Leukemia										
Male	2	1.6	nc	(nc-nc)						

Liver and Intrahepatic Bile Ducts	Female	1	1.4	nc	(nc-nc)
	Male	0	1.0	nc	(nc-nc)
Lung and Bronchus	Female	0	0.4	nc	(nc-nc)
	Male	7	10.9	64.2	(25.7-132.3)
	Female	20	9.9	201.6	(123.1-311.4)

Uteri Corpus and Uterus, NOS	Female	1	1.6	nc	(nc-nc)
All Sites / Types	Female	3	4.3	nc	(nc-nc)
	Male	80	73.3	109.2	(86.6-135.9)
	Female	88	69.3	127.0	(101.9-156.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

30
Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	6	5.3	112.2	(41.0-244.2)
Female	2	2.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	23	23.9	96.1	(60.9-144.2)
Cervix Uteri				
Female	0	1.2	nc	(nc-nc)
Colon / Rectum				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	3.0	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)
Multiple Myeloma				
Male	2	0.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	3	2.9	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	2.1	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Ovary				

Esophagus	Male	15	8.3	180.2	(100.8-297.2)	Pancreas	Female	7	2.5	282.4	(113.1-581.9)
	Female	5	9.7	51.3	(16.5-119.8)						
Hodgkin Lymphoma	Male	2	1.3	nc	(nc-nc)	Prostate	Male	2	1.5	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)						
Kidney & Renal Pelvis	Male	0	0.6	nc	(nc-nc)	Stomach	Male	24	21.9	109.7	(70.3-163.3)
	Female	0	0.5	nc	(nc-nc)						
Larynx	Male	5	2.2	223.0	(71.9-520.4)	Testis	Male	0	1.4	nc	(nc-nc)
	Female	1	1.7	nc	(nc-nc)						
Leukemia	Male	0	1.0	nc	(nc-nc)	Thyroid	Male	0	1.2	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)						
Liver and Intrahepatic Bile Ducts	Male	3	1.8	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Male	0	0.7	nc	(nc-nc)
	Female	5	1.7	290.9	(93.7-678.9)						
Lung and Bronchus	Male	0	1.0	nc	(nc-nc)	All Sites / Types	Female	2	2.1	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)						
	Male	14	10.6	131.9	(72.1-221.4)		Male	85	74.0	114.8	(91.7-141.9)
	Female	24	10.6	226.4	(145.0-336.8)						
	Male	0	1.0	nc	(nc-nc)		Female	4	4.6	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)						
	Male	14	10.6	131.9	(72.1-221.4)		Male	85	74.0	114.8	(91.7-141.9)
	Female	24	10.6	226.4	(145.0-336.8)						
	Male	14	10.6	131.9	(72.1-221.4)		Male	85	74.0	114.8	(91.7-141.9)
	Female	24	10.6	226.4	(145.0-336.8)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	89	73.0	121.9	(97.9-150.1)	Male	63	33.2	189.9	(145.9-243.0)
Female	32	25.3	126.6	(86.6-178.7)	Female	39	24.4	159.6	(113.5-218.2)
Brain and Other Nervous System					Multiple Myeloma				
Male	12	11.7	102.1	(52.7-178.4)	Male	9	9.9	91.1	(41.6-173.0)
Female	10	10.0	99.8	(47.8-183.6)	Female	5	7.9	63.3	(20.4-147.7)
Breast					Non-Hodgkin Lymphoma				
Male	2	2.1	nc	(nc-nc)	Male	27	33.5	80.6	(53.1-117.2)
Female	247	243.9	101.3	(89.0-114.7)	Female	24	30.3	79.1	(50.7-117.7)
Cervix Uteri					Oral Cavity & Pharynx				
Female	10	10.3	97.1	(46.5-178.6)	Male	19	24.3	78.2	(47.1-122.1)
Colon / Rectum					Female	14	12.1	116.2	(63.5-194.9)
Male	95	110.7	85.8	(69.4-104.9)	Ovary				
Female	97	103.3	93.9	(76.1-114.6)	Female	21	25.0	83.8	(51.9-128.2)
Esophagus					Pancreas				
Male	18	16.7	108.1	(64.0-170.8)	Male	22	20.4	107.9	(67.6-163.3)
Female	7	5.1	138.4	(55.4-285.2)	Female	32	21.6	147.9	(101.2-208.8)
Hodgkin Lymphoma					Prostate				
Male	6	4.4	136.9	(50.0-298.1)	Male	346	280.9	123.2	(110.5-136.9)
Female	5	3.8	132.8	(42.8-310.0)	Stomach				
Kidney & Renal Pelvis					Male	19	18.9	100.7	(60.6-157.3)
Male	32	26.4	121.2	(82.9-171.1)	Female	8	10.9	73.6	(31.7-144.9)
Female	19	17.4	109.2	(65.7-170.5)	Testis				
Larynx					Male	8	6.7	118.8	(51.2-234.2)
Male	9	12.1	74.4	(34.0-141.3)					

Female	6	3.1	192.5	(70.3-419.0)
Leukemia				
Male	20	20.6	97.1	(59.3-150.0)
Female	22	16.5	133.6	(83.7-202.3)
Liver and Intrahepatic Bile Ducts				
Male	12	12.3	97.6	(50.4-170.5)
Female	4	4.8	nc	(nc-nc)
Lung and Bronchus				
Male	130	139.8	93.0	(77.7-110.4)
Female	131	116.0	112.9	(94.4-134.0)

Thyroid

Male	7	5.4	129.3	(51.8-266.5)
Female	9	16.7	54.0	(24.6-102.5)

Uteri Corpus and Uterus, NOS

Female	47	48.6	96.7	(71.1-128.7)
--------	----	------	------	--------------

All Sites / Types

Male	993	924.0	107.5	(100.9-114.4)
Female	843	818.0	103.1	(96.2-110.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

32

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	5.2	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Breast				
Male	1	0.2	nc	(nc-nc)
Female	17	19.7	86.2	(50.2-138.0)
Cervix Uteri				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	2.7	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.7	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	3	2.7	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)
Oral Cavity & Pharynx				

Colon / Rectum	Female	3	1.0	nc	(nc-nc)	Ovary	Male	1	2.0	nc	(nc-nc)
	Male	6	8.0	74.6	(27.2-162.3)		Female	2	0.9	nc	(nc-nc)
	Female	3	7.7	nc	(nc-nc)		Female	2	2.0	nc	(nc-nc)
Esophagus	Male	1	1.2	nc	(nc-nc)	Pancreas	Male	0	1.5	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	0.4	nc	(nc-nc)		Female	1	1.6	nc	(nc-nc)
	Male	0	0.5	nc	(nc-nc)		Prostate	Male	15	20.3	73.8
	Female	0	0.4	nc	(nc-nc)	Male		0	1.4	nc	(nc-nc)
Kidney & Renal Pelvis	Male	3	2.1	nc	(nc-nc)	Female		1	0.8	nc	(nc-nc)
Larynx	Female	3	1.3	nc	(nc-nc)	Testis	Male	0	0.8	nc	(nc-nc)
	Male	0	0.9	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	1	1.6	nc	(nc-nc)
Leukemia	Male	2	1.7	nc	(nc-nc)	Thyroid	Male	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	1	1.3	nc	(nc-nc)		Female	1	1.6	nc	(nc-nc)
	Male	0	1.0	nc	(nc-nc)		Uteri Corpus and Uterus, NOS	Female	0	3.8	nc
	Female	0	0.4	nc	(nc-nc)	Male		51	69.3	73.6	(54.8-96.8)
Lung and Bronchus	Male	13	10.1	128.8	(68.5-220.2)	All Sites / Types		Female	53	64.2	82.5
	Female	11	8.6	128.4	(64.0-229.8)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

33

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	2.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	9	7.1	127.2	(58.0-241.5)	Female	2	0.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Colon / Rectum					Female	0	0.3	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Ovary				
Female	4	2.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	0.6	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.2	nc	(nc-nc)	Male	1	9.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	1	0.6	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)					

Larynx	Female	0	0.5	nc	(nc-nc)	Testis	Female	0	0.2	nc	(nc-nc)
	Male	0	0.4	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
Leukemia	Female	0	0.1	nc	(nc-nc)	Thyroid					
	Male	1	0.7	nc	(nc-nc)		Male	1	0.2	nc	(nc-nc)
	Female	1	0.4	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.4	nc	(nc-nc)						
	Female	0	0.1	nc	(nc-nc)		Female	2	1.4	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	2	4.5	nc	(nc-nc)		Male	16	30.4	52.7	(30.1-85.5)
	Female	1	3.0	nc	(nc-nc)		Female	24	21.9	109.6	(70.2-163.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

34

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	20	19.2	104.4	(63.7-161.2)	Male	17	8.9	190.7	(111.0-305.3)
Female	8	5.4	148.4	(63.9-292.4)	Female	10	5.6	178.0	(85.2-327.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	3.2	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Cervix Uteri	Male	0	0.5	nc	(nc-nc)
	Female	62	54.9	113.0	(86.6-144.8)
Colon / Rectum	Female	3	2.4	nc	(nc-nc)
	Male	18	29.2	61.7	(36.6-97.6)
Esophagus	Female	23	22.0	104.4	(66.1-156.6)
	Male	3	4.4	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	1.1	nc	(nc-nc)
	Male	0	1.2	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.9	nc	(nc-nc)
	Male	5	7.1	70.5	(22.7-164.5)
Larynx	Female	5	3.8	132.5	(42.7-309.2)
	Male	1	3.2	nc	(nc-nc)
Leukemia	Female	1	0.7	nc	(nc-nc)
	Male	4	5.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	4	3.7	nc	(nc-nc)
	Male	2	3.3	nc	(nc-nc)
Lung and Bronchus	Female	2	1.0	nc	(nc-nc)
	Male	24	36.9	65.0	(41.7-96.8)
	Female	19	24.4	77.7	(46.8-121.4)

Oral Cavity & Pharynx	Male	15	8.9	167.7	(93.8-276.6)
	Female	4	6.5	nc	(nc-nc)
Ovary	Male	4	6.6	nc	(nc-nc)
	Female	4	2.7	nc	(nc-nc)
Pancreas	Female	6	5.6	107.1	(39.1-233.0)
	Male	7	5.4	130.0	(52.1-267.9)
Prostate	Female	5	4.6	108.8	(35.1-253.9)
	Male	67	74.8	89.5	(69.4-113.7)
Stomach	Male	4	5.0	nc	(nc-nc)
	Female	2	2.4	nc	(nc-nc)
Testis	Male	2	1.9	nc	(nc-nc)
	Male	2	1.5	nc	(nc-nc)
Thyroid	Female	8	4.0	197.9	(85.2-390.0)
	Male	2	1.5	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	16	10.9	147.4	(84.2-239.3)
	Male	215	245.5	87.6	(76.2-100.1)
All Sites / Types	Female	202	180.0	112.2	(97.3-128.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

35

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	10.3	87.5	(39.9-166.2)	Male	8	6.0	133.6	(57.5-263.2)
Female	5	3.6	139.9	(45.1-326.4)	Female	7	5.0	138.9	(55.6-286.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	2.4	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	7	5.8	121.0	(48.5-249.4)
Female	40	45.2	88.6	(63.3-120.6)	Female	6	4.9	123.6	(45.1-269.0)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	2.4	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Colon / Rectum					Female	3	2.0	nc	(nc-nc)
Male	13	16.2	80.4	(42.8-137.5)	Ovary				
Female	9	14.4	62.6	(28.6-118.9)	Female	3	4.5	nc	(nc-nc)
Esophagus					Pancreas				
Male	4	2.6	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	1.1	nc	(nc-nc)	Male	38	42.0	90.5	(64.0-124.2)
Female	0	1.0	nc	(nc-nc)					

Kidney & Renal Pelvis						Stomach				
Male	1	4.5	nc	(nc-nc)		Male	2	2.8	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)		Female	2	1.5	nc	(nc-nc)
Larynx						Testis				
Male	2	2.0	nc	(nc-nc)		Male	2	2.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)						
Leukemia						Thyroid				
Male	3	3.5	nc	(nc-nc)		Male	1	1.3	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)		Female	3	4.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	3	2.1	nc	(nc-nc)						
Female	0	0.7	nc	(nc-nc)		Female	8	8.4	95.0	(40.9-187.1)
Lung and Bronchus						All Sites / Types				
Male	18	20.3	88.5	(52.4-139.8)		Male	129	143.9	89.6	(74.8-106.5)
Female	15	17.1	87.8	(49.1-144.8)		Female	127	137.1	92.7	(77.2-110.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

36
Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	12	12.9	92.9	(47.9-162.3)	Male	8	7.5	107.3	(46.2-211.4)
Female	4	4.6	nc	(nc-nc)	Female	9	6.2	145.2	(66.3-275.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	3.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)

Breast	Female	4	2.4	nc	(nc-nc)
	Male	0	0.4	nc	(nc-nc)
Cervix Uteri	Female	36	56.2	64.0	(44.8-88.6)
	Male				
Colon / Rectum	Female	3	2.9	nc	(nc-nc)
	Male	27	20.4	132.5	(87.3-192.9)
Esophagus	Female	9	18.1	49.8	(22.7-94.6)
	Male	2	3.4	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	0.9	nc	(nc-nc)
	Male	3	1.4	nc	(nc-nc)
Kidney & Renal Pelvis	Female	1	1.1	nc	(nc-nc)
	Male	6	5.8	103.5	(37.8-225.3)
Larynx	Female	2	3.6	nc	(nc-nc)
	Male	4	2.6	nc	(nc-nc)
Leukemia	Female	0	0.7	nc	(nc-nc)
	Male	4	4.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	4	3.4	nc	(nc-nc)
	Male	1	2.7	nc	(nc-nc)
Lung and Bronchus	Female	0	0.9	nc	(nc-nc)
	Male				

Non-Hodgkin Lymphoma	Female	0	1.5	nc	(nc-nc)
	Male	7	7.2	97.7	(39.1-201.2)
Oral Cavity & Pharynx	Female	6	6.2	97.5	(35.6-212.3)
	Male	7	5.7	122.3	(49.0-252.0)
Ovary	Female	3	2.6	nc	(nc-nc)
	Male				
Pancreas	Female	5	5.6	89.1	(28.7-208.0)
	Male	2	3.8	nc	(nc-nc)
Prostate	Female	7	3.7	187.9	(75.3-387.1)
	Male	61	57.7	105.6	(80.8-135.7)
Stomach	Female				
	Male	6	3.4	175.2	(64.0-381.4)
Testis	Female	2	1.8	nc	(nc-nc)
	Male	2	2.6	nc	(nc-nc)
Thyroid	Female				
	Male	2	1.6	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	4	5.2	nc	(nc-nc)
	Male				
All Sites / Types	Female	8	11.1	72.4	(31.2-142.6)
	Male				

Male	29	26.4	109.7	(73.4-157.5)
Female	23	22.7	101.4	(64.3-152.2)

Male	201	186.5	107.8	(93.4-123.8)
Female	144	172.9	83.3	(70.2-98.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

37

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	28	30.4	92.1	(61.2-133.1)	Male	18	14.7	122.4	(72.5-193.4)
Female	10	12.0	83.5	(40.0-153.6)	Female	20	12.5	160.2	(97.8-247.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	5.4	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	5	5.0	100.4	(32.3-234.2)	Female	1	3.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.9	nc	(nc-nc)	Male	11	14.7	74.9	(37.4-134.1)
Female	133	119.3	111.5	(93.3-132.1)	Female	20	14.6	137.1	(83.7-211.7)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	5.4	nc	(nc-nc)	Male	5	10.9	45.8	(14.7-106.8)
Colon / Rectum					Female	10	5.8	171.3	(82.0-315.1)
Male	49	46.5	105.3	(77.9-139.2)	Ovary				
Female	48	49.8	96.4	(71.1-127.8)	Female	18	12.3	146.6	(86.8-231.7)
Esophagus					Pancreas				
Male	11	7.1	153.9	(76.7-275.4)	Male	14	8.6	162.4	(88.7-272.4)
Female	3	2.4	nc	(nc-nc)	Female	9	10.3	87.1	(39.7-165.4)

Hodgkin Lymphoma					Prostate				
Male	3	2.2	nc	(nc-nc)	Male	103	119.5	86.2	(70.3-104.5)
Female	3	2.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	6	11.5	52.1	(19.0-113.4)	Male	6	8.0	75.2	(27.5-163.6)
Female	6	8.2	72.9	(26.6-158.7)	Female	3	5.4	nc	(nc-nc)
Larynx					Testis				
Male	4	5.2	nc	(nc-nc)	Male	7	3.7	188.0	(75.3-387.3)
Female	2	1.4	nc	(nc-nc)					
Leukemia					Thyroid				
Male	6	9.0	66.9	(24.4-145.7)	Male	3	2.6	nc	(nc-nc)
Female	11	8.1	135.3	(67.4-242.0)	Female	10	9.1	109.7	(52.5-201.8)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	4	5.4	nc	(nc-nc)					
Female	2	2.3	nc	(nc-nc)	Female	21	23.3	90.3	(55.9-138.0)
Lung and Bronchus					All Sites / Types				
Male	26	58.3	44.6	(29.1-65.3)	Male	335	395.2	84.8	(75.9-94.4)
Female	47	53.5	87.9	(64.6-116.9)	Female	409	396.4	103.2	(93.4-113.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

38

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	3.8	133.0	(42.9-310.4)	Male	2	2.4	nc	(nc-nc)

Brain and Other Nervous System	Female	1	1.2	nc	(nc-nc)	Multiple Myeloma	Female	3	2.0	nc	(nc-nc)
	Male	1	1.0	nc	(nc-nc)		Male	1	0.6	nc	(nc-nc)
	Female	2	0.8	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Breast	Male	0	0.1	nc	(nc-nc)	Non-Hodgkin Lymphoma	Male	2	2.3	nc	(nc-nc)
	Female	21	17.1	122.9	(76.1-187.9)		Female	4	1.8	nc	(nc-nc)
Cervix Uteri	Female	0	1.0	nc	(nc-nc)	Oral Cavity & Pharynx	Male	0	1.9	nc	(nc-nc)
	Male	6	6.0	99.5	(36.3-216.6)		Female	2	0.8	nc	(nc-nc)
	Female	2	4.8	nc	(nc-nc)						
Colon / Rectum	Male	3	1.0	nc	(nc-nc)	Ovary	Female	1	1.7	nc	(nc-nc)
	Female	2	0.2	nc	(nc-nc)						
Esophagus	Male	0	0.5	nc	(nc-nc)	Pancreas	Male	1	1.1	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	2	1.0	nc	(nc-nc)
Hodgkin Lymphoma	Male	0	0.5	nc	(nc-nc)	Prostate	Male	19	17.1	110.9	(66.7-173.1)
	Female	0	0.4	nc	(nc-nc)						
Kidney & Renal Pelvis	Male	2	1.8	nc	(nc-nc)	Stomach	Male	1	1.0	nc	(nc-nc)
	Female	0	1.0	nc	(nc-nc)		Female	1	0.5	nc	(nc-nc)
Larynx	Male	0	0.8	nc	(nc-nc)	Testis	Male	0	0.9	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)						
Leukemia	Male	2	1.4	nc	(nc-nc)	Thyroid	Male	0	0.6	nc	(nc-nc)
	Female	0	1.0	nc	(nc-nc)		Female	3	1.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					

Male	0	0.9	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	6	7.8	77.3	(28.2-168.3)	Male	53	56.6	93.6	(70.1-122.4)
Female	5	6.0	83.2	(26.8-194.2)	Female	57	50.4	113.2	(85.7-146.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

39
Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	2.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	16	9.9	161.9	(92.5-263.0)	Female	1	1.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.5	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
					Female	0	0.5	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	4	4.1	nc	(nc-nc)					
Female	8	3.5	231.4	(99.7-456.0)	Female	1	1.0	nc	(nc-nc)

Esophagus						Pancreas				
Male	0	0.7	nc	(nc-nc)		Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)		Female	0	0.7	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	1	0.2	nc	(nc-nc)		Male	9	11.3	79.5	(36.3-150.9)
Female	0	0.2	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	0	1.1	nc	(nc-nc)		Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Larynx						Testis				
Male	0	0.5	nc	(nc-nc)		Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)						
Leukemia						Thyroid				
Male	0	0.8	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)		Female	2	0.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	0.5	nc	(nc-nc)						
Female	1	0.2	nc	(nc-nc)		Female	2	1.9	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	3	5.2	nc	(nc-nc)		Male	30	36.2	82.9	(55.9-118.3)
Female	4	4.2	nc	(nc-nc)		Female	40	31.0	129.2	(92.3-175.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	2.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	11	10.1	109.3	(54.5-195.6)	Female	1	1.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
					Female	0	0.5	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	7	4.3	164.6	(66.0-339.2)					
Female	6	3.9	154.4	(56.4-336.1)	Female	2	1.0	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	0.2	nc	(nc-nc)	Male	10	11.2	89.5	(42.8-164.6)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	2	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Larynx					Testis				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Leukemia					Thyroid				

Male	0	0.8	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.5	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	5	2.0	255.3	(82.3-595.7)
Lung and Bronchus					All Sites / Types				
Male	2	5.4	nc	(nc-nc)	Male	30	36.6	82.0	(55.3-117.1)
Female	2	4.4	nc	(nc-nc)	Female	40	32.4	123.6	(88.3-168.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

41

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	44	43.3	101.6	(73.8-136.4)	Male	27	22.0	122.5	(80.7-178.3)
Female	15	17.9	84.0	(47.0-138.5)	Female	24	18.8	127.9	(81.9-190.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	20	8.3	241.5	(147.5-373.0)	Male	7	6.0	116.0	(46.5-238.9)
Female	6	7.6	79.2	(28.9-172.5)	Female	4	5.6	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	2	1.3	nc	(nc-nc)	Male	18	21.8	82.7	(49.0-130.7)
Female	184	177.0	103.9	(89.5-120.1)	Female	22	21.9	100.5	(62.9-152.1)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	14	16.3	85.7	(46.8-143.9)
Female	5	8.1	61.4	(19.8-143.2)	Female	13	8.7	149.4	(79.5-255.5)

Colon / Rectum					Ovary				
Male	59	66.7	88.4	(67.3-114.0)					
Female	73	74.2	98.4	(77.1-123.7)	Female	20	18.3	109.4	(66.8-168.9)
Esophagus					Pancreas				
Male	7	10.4	67.2	(26.9-138.4)	Male	16	12.4	129.1	(73.7-209.7)
Female	2	3.6	nc	(nc-nc)	Female	16	15.4	103.8	(59.3-168.6)
Hodgkin Lymphoma					Prostate				
Male	6	3.6	166.0	(60.6-361.3)	Male	136	174.6	77.9	(65.4-92.1)
Female	2	3.3	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	18	17.2	104.9	(62.2-165.9)	Male	6	11.4	52.9	(19.3-115.1)
Female	15	12.3	121.7	(68.1-200.7)	Female	4	8.0	nc	(nc-nc)
Larynx					Testis				
Male	9	7.7	116.8	(53.3-221.7)	Male	6	6.3	94.6	(34.5-205.9)
Female	5	2.1	232.6	(75.0-542.9)					
Leukemia					Thyroid				
Male	11	13.3	82.8	(41.3-148.1)	Male	5	4.2	119.5	(38.5-278.9)
Female	11	12.3	89.3	(44.5-159.8)	Female	10	13.9	71.9	(34.4-132.3)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	4	8.0	nc	(nc-nc)					
Female	4	3.5	nc	(nc-nc)	Female	28	34.4	81.5	(54.1-117.7)
Lung and Bronchus					All Sites / Types				
Male	82	84.7	96.8	(77.0-120.2)	Male	537	577.4	93.0	(85.3-101.2)
Female	98	79.9	122.6	(99.5-149.4)	Female	617	591.6	104.3	(96.2-112.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	35	29.4	119.1	(82.9-165.6)	Male	14	18.0	77.8	(42.5-130.5)
Female	10	10.6	94.6	(45.3-174.0)	Female	11	14.7	74.7	(37.2-133.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	7.4	nc	(nc-nc)	Male	9	4.3	207.2	(94.5-393.3)
Female	6	5.7	104.6	(38.2-227.7)	Female	5	3.3	151.8	(48.9-354.2)
Breast					Non-Hodgkin Lymphoma				
Male	2	1.0	nc	(nc-nc)	Male	17	17.1	99.1	(57.7-158.7)
Female	127	132.5	95.8	(79.9-114.0)	Female	10	14.2	70.6	(33.8-129.8)
Cervix Uteri					Oral Cavity & Pharynx				
Female	6	6.9	87.0	(31.8-189.3)	Male	12	13.9	86.3	(44.6-150.8)
Colon / Rectum					Ovary				
Male	49	46.8	104.6	(77.4-138.3)	Female	12	13.2	90.7	(46.8-158.5)
Female	45	41.4	108.7	(79.3-145.4)	Pancreas				
Esophagus					Male	6	8.9	67.7	(24.7-147.3)
Male	11	8.0	138.1	(68.9-247.2)	Female	8	8.5	94.4	(40.7-186.1)
Female	2	2.0	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	162	134.1	120.8	(102.9-140.9)
Male	6	3.6	164.5	(60.1-358.0)	Stomach				
Female	2	2.8	nc	(nc-nc)	Male	3	7.9	nc	(nc-nc)
Kidney & Renal Pelvis					Female	0	4.3	nc	(nc-nc)
Male	19	13.8	137.6	(82.8-214.9)	Testis				
Female	4	8.3	nc	(nc-nc)					
Larynx									

Male	3	6.1	nc	(nc-nc)	Male	6	7.0	85.9	(31.4-187.0)
Female	2	1.5	nc	(nc-nc)					
Leukemia					Thyroid				
Male	6	10.4	57.9	(21.1-125.9)	Male	2	4.1	nc	(nc-nc)
Female	12	8.0	149.2	(77.0-260.7)	Female	17	12.6	135.4	(78.8-216.9)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	4	6.4	nc	(nc-nc)					
Female	7	2.0	343.6	(137.7-708.0)	Female	15	26.2	57.3	(32.0-94.5)
Lung and Bronchus					All Sites / Types				
Male	74	60.4	122.4	(96.1-153.7)	Male	475	436.1	108.9	(99.3-119.2)
Female	69	51.3	134.4	(104.6-170.1)	Female	406	403.0	100.8	(91.2-111.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

43

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	7.4	81.4	(29.7-177.2)	Male	1	4.2	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	30	31.6	94.9	(64.0-135.4)	Female	4	3.6	nc	(nc-nc)

Cervix Uteri					Oral Cavity & Pharynx				
	Male	2	3.1	nc	(nc-nc)				
	Female	2	1.5	nc	(nc-nc)				
Colon / Rectum					Ovary				
	Male	11	11.5	95.6	(47.6-171.0)				
	Female	8	11.1	71.9	(30.9-141.6)				
Esophagus					Pancreas				
	Male	0	1.8	nc	(nc-nc)				
	Female	3	0.5	nc	(nc-nc)				
Hodgkin Lymphoma					Prostate				
	Male	2	0.8	nc	(nc-nc)				
	Female	0	0.7	nc	(nc-nc)				
Kidney & Renal Pelvis					Stomach				
	Male	6	3.1	190.8	(69.7-415.3)				
	Female	1	2.1	nc	(nc-nc)				
Larynx					Testis				
	Male	2	1.4	nc	(nc-nc)				
	Female	0	0.4	nc	(nc-nc)				
Leukemia					Thyroid				
	Male	6	2.5	240.9	(88.0-524.3)				
	Female	0	2.0	nc	(nc-nc)				
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
	Male	1	1.5	nc	(nc-nc)				
	Female	1	0.5	nc	(nc-nc)				
Lung and Bronchus					All Sites / Types				
	Male	16	14.5	110.4	(63.1-179.3)				
	Female	11	13.1	83.9	(41.8-150.1)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

44

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	1.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	5	4.8	103.2	(33.3-240.8)	Female	0	0.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
					Female	0	0.2	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	0	2.0	nc	(nc-nc)					
Female	1	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	0	0.6	nc	(nc-nc)	Testis	Male	1	0.3	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)		Male	1	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)						
Leukemia	Male	0	0.4	nc	(nc-nc)	Thyroid	Male	0	0.1	nc	(nc-nc)
	Female	1	0.3	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.3	nc	(nc-nc)						
	Female	0	0.1	nc	(nc-nc)		Female	0	0.9	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	1	2.6	nc	(nc-nc)		Male	12	18.3	65.5	(33.8-114.3)
	Female	2	1.8	nc	(nc-nc)		Female	12	14.3	83.7	(43.2-146.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

45

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	3.2	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
	Male	0	0.1	nc	(nc-nc)		Male	1	1.9	nc (nc-nc)
	Female	19	15.1	126.1	(75.9-196.9)		Female	0	1.4	nc (nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
	Female	0	0.8	nc	(nc-nc)		Male	1	1.7	nc (nc-nc)
							Female	0	0.6	nc (nc-nc)
Colon / Rectum						Ovary				
	Male	3	5.3	nc	(nc-nc)					
	Female	6	3.9	153.7	(56.1-334.6)		Female	3	1.5	nc (nc-nc)
Esophagus						Pancreas				
	Male	2	0.9	nc	(nc-nc)		Male	4	1.0	nc (nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.8	nc (nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.4	nc	(nc-nc)		Male	11	15.3	71.7 (35.7-128.3)
	Female	0	0.3	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	1	1.6	nc	(nc-nc)		Male	2	0.9	nc (nc-nc)
	Female	0	0.9	nc	(nc-nc)		Female	0	0.4	nc (nc-nc)
Larynx						Testis				
	Male	0	0.7	nc	(nc-nc)		Male	1	0.6	nc (nc-nc)
	Female	0	0.2	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	1.2	nc	(nc-nc)		Male	2	0.5	nc (nc-nc)
	Female	0	0.8	nc	(nc-nc)		Female	2	1.4	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.8	nc	(nc-nc)					
	Female	0	0.2	nc	(nc-nc)		Female	4	2.9	nc (nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	4	6.8	nc	(nc-nc)		Male	42	49.4	85.0 (61.2-114.9)

Female 7 5.1 137.3 (55.0-282.9)

Female 45 42.6 105.7 (77.1-141.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

46
Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	350	445.4	78.6	(70.6-87.3)	Male	204	246.1	82.9	(71.9-95.1)
Female	150	184.0	81.5	(69.0-95.7)	Female	172	228.3	75.3	(64.5-87.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	79	99.6	79.3	(62.8-98.9)	Male	72	62.4	115.4	(90.3-145.4)
Female	74	89.1	83.1	(65.2-104.3)	Female	63	57.3	110.0	(84.5-140.7)
Breast					Non-Hodgkin Lymphoma				
Male	14	13.6	102.6	(56.1-172.2)	Male	272	243.1	111.9	(99.0-126.0)
Female	1808	1924.4	94.0	(89.7-98.4)	Female	248	237.8	104.3	(91.7-118.1)
Cervix Uteri					Oral Cavity & Pharynx				
Female	140	101.1	138.5	(116.5-163.4)	Male	245	173.9	140.9	(123.8-159.7)
					Female	106	95.3	111.3	(91.1-134.6)
Colon / Rectum					Ovary				
Male	707	690.9	102.3	(94.9-110.2)					
Female	833	752.2	110.7	(103.3-118.5)	Female	181	200.7	90.2	(77.5-104.3)
Esophagus					Pancreas				
Male	100	107.7	92.8	(75.5-112.9)	Male	143	127.9	111.8	(94.2-131.7)
Female	44	36.8	119.7	(87.0-160.7)	Female	161	155.8	103.3	(88.0-120.6)
Hodgkin Lymphoma					Prostate				

Male	48	57.3	83.8	(61.7-111.0)	Male	1990	1789.2	111.2	(106.4-116.2)
Female	54	50.9	106.2	(79.8-138.5)					
Kidney & Renal Pelvis					Stomach				
Male	197	181.0	108.8	(94.2-125.1)	Male	171	118.3	144.5	(123.7-167.9)
Female	148	131.9	112.2	(94.8-131.8)	Female	137	80.7	169.7	(142.5-200.6)
Larynx					Testis				
Male	113	80.1	141.1	(116.3-169.7)	Male	79	111.3	71.0	(56.2-88.4)
Female	32	23.2	138.2	(94.5-195.1)					
Leukemia					Thyroid				
Male	149	149.0	100.0	(84.6-117.4)	Male	66	54.3	121.5	(94.0-154.6)
Female	123	135.1	91.0	(75.7-108.6)	Female	209	190.5	109.7	(95.3-125.6)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	162	83.9	193.2	(164.6-225.3)					
Female	58	36.0	161.2	(122.4-208.3)	Female	395	374.6	105.4	(95.3-116.4)
Lung and Bronchus					All Sites / Types				
Male	966	867.7	111.3	(104.4-118.6)	Male	6667	6114.6	109.0	(106.4-111.7)
Female	901	840.2	107.2	(100.3-114.5)	Female	6581	6395.0	102.9	(100.4-105.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	26	23.9	108.8	(71.0-159.4)	Male	15	11.3	132.4	(74.0-218.3)
Female	7	8.4	83.7	(33.5-172.5)	Female	11	8.5	130.1	(64.9-232.8)

Brain and Other Nervous System						Multiple Myeloma				
Male	2	4.2	nc	(nc-nc)		Male	5	3.3	152.8	(49.2-356.6)
Female	4	3.5	nc	(nc-nc)		Female	5	2.6	190.9	(61.5-445.4)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.7	nc	(nc-nc)		Male	5	11.4	43.9	(14.2-102.5)
Female	91	82.6	110.2	(88.7-135.3)		Female	11	10.2	108.3	(54.0-193.8)
Cervix Uteri						Oral Cavity & Pharynx				
Female	2	3.6	nc	(nc-nc)		Male	8	8.4	95.2	(41.0-187.6)
Colon / Rectum						Female	7	4.1	171.2	(68.6-352.8)
Male	50	36.5	137.0	(101.6-180.6)		Ovary				
Female	47	33.9	138.5	(101.8-184.2)		Female	8	8.5	94.2	(40.5-185.5)
Esophagus						Pancreas				
Male	11	5.6	195.1	(97.3-349.2)		Male	3	6.7	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)		Female	7	7.1	98.6	(39.5-203.2)
Hodgkin Lymphoma						Prostate				
Male	3	1.8	nc	(nc-nc)		Male	133	96.5	137.9	(115.4-163.4)
Female	2	1.4	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	6	6.2	97.3	(35.5-211.7)
Male	8	9.0	88.6	(38.1-174.6)		Female	4	3.6	nc	(nc-nc)
Female	5	5.8	85.5	(27.5-199.5)		Testis				
Larynx						Male	0	2.8	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)		Thyroid				
Female	0	1.1	nc	(nc-nc)		Male	2	2.0	nc	(nc-nc)
Leukemia						Female	7	6.0	117.5	(47.1-242.1)
Male	9	7.0	128.4	(58.6-243.8)		Uteri Corpus and Uterus, NOS				
Female	6	5.6	107.3	(39.2-233.6)						
Liver and Intrahepatic Bile Ducts										
Male	7	4.2	167.4	(67.0-344.8)						

Female	2	1.6	nc	(nc-nc)	Female	23	16.7	138.1	(87.5-207.2)
Lung and Bronchus					All Sites / Types				
Male	50	46.8	106.8	(79.3-140.8)	Male	364	312.7	116.4	(104.8-129.0)
Female	57	38.7	147.1	(111.4-190.6)	Female	336	275.2	122.1	(109.4-135.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

48

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	2.9	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	14	14.3	98.1	(53.6-164.6)	Female	1	1.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.8	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Colon / Rectum					Female	0	0.6	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	Ovary				
Female	2	3.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Esophagus					Pancreas				

Hodgkin Lymphoma	Male	0	0.8	nc	(nc-nc)	Prostate	Male	0	0.9	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	1	0.7	nc	(nc-nc)
Kidney & Renal Pelvis	Male	0	0.4	nc	(nc-nc)	Stomach	Male	10	13.0	77.0	(36.9-141.6)
	Female	0	0.3	nc	(nc-nc)		Female	1	0.3	nc	(nc-nc)
Larynx	Male	0	0.6	nc	(nc-nc)	Testis	Male	1	0.8	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	5	1.6	316.5	(102.0-738.6)
Leukemia	Male	1	1.1	nc	(nc-nc)	Thyroid	Male	4	0.5	nc	(nc-nc)
	Female	0	0.8	nc	(nc-nc)		Female	5	2.7	187.6	(60.5-437.8)
Liver and Intrahepatic Bile Ducts	Male	0	0.7	nc	(nc-nc)	All Sites / Types	Male	31	44.4	69.8	(47.4-99.1)
	Female	0	0.2	nc	(nc-nc)		Female	38	39.7	95.8	(67.8-131.4)
Lung and Bronchus	Male	4	5.9	nc	(nc-nc)						
	Female	3	4.5	nc	(nc-nc)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	4	7.7	nc	(nc-nc)		Male	7	4.4	158.9	(63.6-327.3)
Female	2	2.4	nc	(nc-nc)		Female	4	3.3	nc	(nc-nc)
Brain and Other Nervous System						Multiple Myeloma				
Male	1	1.7	nc	(nc-nc)		Male	1	1.1	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)		Female	1	0.7	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)		Male	5	4.2	118.6	(38.2-276.7)
Female	33	32.2	102.6	(70.6-144.1)		Female	0	3.2	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
Female	0	1.6	nc	(nc-nc)		Male	5	3.6	138.1	(44.5-322.3)
Colon / Rectum						Female	6	1.4	426.1	(155.6-927.4)
Male	17	12.2	139.3	(81.1-223.1)		Ovary				
Female	8	9.2	86.7	(37.3-170.9)		Female	4	3.1	nc	(nc-nc)
Esophagus						Pancreas				
Male	1	2.1	nc	(nc-nc)		Male	0	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)		Female	3	1.9	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	1	0.7	nc	(nc-nc)		Male	34	35.4	95.9	(66.4-134.1)
Female	0	0.5	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	1	2.1	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)		Female	1	0.9	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)		Testis				
Larynx						Male	0	1.1	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)		Thyroid				
Female	0	0.4	nc	(nc-nc)		Male	0	0.9	nc	(nc-nc)
Leukemia										
Male	3	2.6	nc	(nc-nc)						

Female	2	1.8	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	3	1.7	nc	(nc-nc)					
Female	1	0.5	nc	(nc-nc)	Female	5	6.3	79.3	(25.5-185.0)
Lung and Bronchus					All Sites / Types				
Male	8	15.8	50.5	(21.7-99.5)	Male	97	111.9	86.7	(70.3-105.7)
Female	14	11.8	118.6	(64.8-199.0)	Female	97	93.6	103.7	(84.1-126.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

50
Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	4.2	nc	(nc-nc)	Male	6	2.3	265.1	(96.8-577.1)
Female	4	1.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	15	16.4	91.7	(51.3-151.3)	Female	1	1.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	1.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Colon / Rectum					Ovary				

	Male	9	6.5	138.3	(63.1-262.6)					
	Female	7	5.4	128.5	(51.5-264.9)		Female	2	1.6	nc (nc-nc)
Esophagus						Pancreas				
	Male	1	1.1	nc	(nc-nc)		Male	1	1.2	nc (nc-nc)
	Female	0	0.3	nc	(nc-nc)		Female	0	1.1	nc (nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.4	nc	(nc-nc)		Male	20	18.1	110.5 (67.4-170.6)
	Female	0	0.3	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	2	1.8	nc	(nc-nc)		Male	0	1.1	nc (nc-nc)
	Female	0	1.1	nc	(nc-nc)		Female	0	0.6	nc (nc-nc)
Larynx						Testis				
	Male	1	0.8	nc	(nc-nc)		Male	0	0.6	nc (nc-nc)
	Female	0	0.2	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	1	1.3	nc	(nc-nc)		Male	0	0.5	nc (nc-nc)
	Female	1	1.0	nc	(nc-nc)		Female	3	1.4	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.8	nc	(nc-nc)					
	Female	0	0.3	nc	(nc-nc)		Female	4	3.2	nc (nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	5	8.4	59.7	(19.2-139.4)		Male	52	58.2	89.3 (66.7-117.2)
	Female	7	6.7	104.6	(41.9-215.5)		Female	45	50.3	89.4 (65.2-119.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

51
Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	48	42.8	112.2	(82.7-148.8)	Male	31	20.6	150.5	(102.2-213.6)
Female	19	17.1	111.4	(67.1-174.0)	Female	26	17.0	152.5	(99.6-223.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	7.6	65.8	(21.2-153.5)	Male	2	5.9	nc	(nc-nc)
Female	8	6.9	115.8	(49.9-228.2)	Female	5	5.3	94.1	(30.3-219.5)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.3	nc	(nc-nc)	Male	18	20.6	87.5	(51.9-138.4)
Female	154	165.8	92.9	(78.8-108.7)	Female	22	20.6	107.0	(67.0-162.0)
Cervix Uteri					Oral Cavity & Pharynx				
Female	10	7.2	138.4	(66.3-254.5)	Male	15	15.3	97.8	(54.7-161.4)
Colon / Rectum					Female	5	8.2	60.7	(19.6-141.8)
Male	87	65.5	132.9	(106.5-164.0)	Ovary				
Female	85	69.7	121.9	(97.4-150.7)	Female	17	17.1	99.5	(57.9-159.3)
Esophagus					Pancreas				
Male	10	10.2	98.5	(47.2-181.1)	Male	14	12.1	115.6	(63.1-193.9)
Female	6	3.4	175.9	(64.2-382.9)	Female	12	14.6	82.3	(42.5-143.7)
Hodgkin Lymphoma					Prostate				
Male	2	3.1	nc	(nc-nc)	Male	153	173.1	88.4	(74.9-103.5)
Female	6	2.8	217.0	(79.2-472.3)	Stomach				
Kidney & Renal Pelvis					Male	12	11.1	108.2	(55.9-189.1)
Male	23	16.4	140.5	(89.0-210.9)	Female	5	7.4	67.5	(21.7-157.4)
Female	7	11.7	59.6	(23.9-122.8)	Testis				
Larynx					Male	3	5.2	nc	(nc-nc)
Male	5	7.5	66.8	(21.5-156.0)					

Female	0	2.1	nc	(nc-nc)
Leukemia				
Male	10	12.6	79.3	(38.0-145.9)
Female	16	11.3	141.3	(80.7-229.5)
Liver and Intrahepatic Bile Ducts				
Male	7	7.6	92.4	(37.0-190.4)
Female	1	3.3	nc	(nc-nc)
Lung and Bronchus				
Male	89	83.7	106.3	(85.3-130.8)
Female	89	77.7	114.5	(91.9-140.9)

Thyroid

Male	2	3.7	nc	(nc-nc)
Female	11	12.0	91.9	(45.8-164.5)
Uteri Corpus and Uterus, NOS				
Female	35	33.1	105.8	(73.7-147.1)
All Sites / Types				
Male	577	562.1	102.7	(94.4-111.4)
Female	581	556.0	104.5	(96.2-113.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

52

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	17	19.1	89.2	(51.9-142.8)
Female	11	6.3	173.7	(86.6-310.8)
Brain and Other Nervous System				
Male	2	2.8	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)
Breast				
Male	2	0.5	nc	(nc-nc)
Female	86	58.7	146.5	(117.1-180.9)
Cervix Uteri				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	8.2	122.1	(58.5-224.6)
Female	12	5.7	210.0	(108.4-366.9)
Multiple Myeloma				
Male	2	2.5	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	8.4	95.5	(41.1-188.1)
Female	10	7.4	134.9	(64.6-248.2)
Oral Cavity & Pharynx				

Colon / Rectum	Female	0	2.3	nc	(nc-nc)	Male	10	5.9	168.7	(80.8-310.2)
	Male	27	28.7	94.2	(62.1-137.1)	Female	2	2.9	nc	(nc-nc)
Esophagus	Female	17	26.1	65.0	(37.9-104.2)	Female	11	6.1	181.7	(90.6-325.1)
	Male	2	4.2	nc	(nc-nc)	Male	6	5.3	114.0	(41.6-248.2)
Hodgkin Lymphoma	Female	4	1.3	nc	(nc-nc)	Female	5	5.5	90.9	(29.3-212.2)
	Male	0	0.9	nc	(nc-nc)	Male	82	70.3	116.7	(92.8-144.8)
Kidney & Renal Pelvis	Female	0	0.8	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
	Male	6	6.5	91.6	(33.5-199.4)	Male	3	4.9	nc	(nc-nc)
Larynx	Female	3	4.2	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
	Male	4	3.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Leukemia	Female	0	0.8	nc	(nc-nc)	Female	0	3.6	nc	(nc-nc)
	Male	6	5.2	116.4	(42.5-253.4)	Male	1	1.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	2	4.0	nc	(nc-nc)	Female	0	3.6	nc	(nc-nc)
	Male	1	3.1	nc	(nc-nc)	Female	11	11.6	94.5	(47.1-169.1)
Lung and Bronchus	Female	0	1.2	nc	(nc-nc)	Female	11	11.6	94.5	(47.1-169.1)
	Male	34	35.9	94.7	(65.6-132.3)	Male	238	233.4	102.0	(89.4-115.8)
	Female	24	28.5	84.3	(54.0-125.5)	Female	218	199.6	109.2	(95.2-124.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

53

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	16	18.6	85.8	(49.0-139.4)	Male	17	11.7	145.3	(84.6-232.6)
Female	6	6.4	93.1	(34.0-202.6)	Female	11	8.6	128.6	(64.1-230.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	4.8	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	5	3.4	146.9	(47.3-342.7)	Female	2	2.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)	Male	13	11.2	116.1	(61.8-198.5)
Female	88	75.6	116.4	(93.4-143.4)	Female	11	8.5	128.9	(64.2-230.6)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	3.9	nc	(nc-nc)	Male	3	8.8	nc	(nc-nc)
Colon / Rectum					Female	1	3.6	nc	(nc-nc)
Male	33	29.7	111.1	(76.5-156.1)	Ovary				
Female	21	25.8	81.3	(50.3-124.2)	Female	11	7.7	143.3	(71.5-256.5)
Esophagus					Pancreas				
Male	4	4.9	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	7	5.3	132.0	(52.9-271.9)
Hodgkin Lymphoma					Prostate				
Male	2	2.6	nc	(nc-nc)	Male	83	80.9	102.6	(81.7-127.2)
Female	2	1.8	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	4	5.1	nc	(nc-nc)
Male	12	8.7	138.2	(71.3-241.4)					

Larynx	Female	8	4.9	162.8	(70.1-320.7)	Testis	Female	0	2.7	nc	(nc-nc)
	Male	2	3.8	nc	(nc-nc)		Male	6	5.1	116.7	(42.6-253.9)
Leukemia	Female	0	0.9	nc	(nc-nc)	Thyroid					
	Male	5	6.7	74.7	(24.1-174.4)		Male	3	2.7	nc	(nc-nc)
	Female	4	4.9	nc	(nc-nc)		Female	13	7.3	178.6	(95.0-305.5)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	5	4.0	123.5	(39.8-288.1)						
	Female	1	1.3	nc	(nc-nc)		Female	14	14.6	95.6	(52.2-160.4)
Lung and Bronchus						All Sites / Types					
	Male	34	37.7	90.2	(62.4-126.0)		Male	274	273.9	100.0	(88.5-112.6)
	Female	23	30.4	75.7	(47.9-113.5)		Female	241	237.4	101.5	(89.1-115.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

54
Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	3.5	172.6	(63.0-375.7)	Male	0	1.9	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Male	0	0.1	nc	(nc-nc)
Female	14	13.3	105.0	(57.4-176.2)
Cervix Uteri				
Female	1	0.6	nc	(nc-nc)
Colon / Rectum				
Male	4	5.4	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)
Esophagus				
Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.5	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)
Larynx				
Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	2	1.1	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	10	6.9	145.3	(69.6-267.3)
Female	2	5.3	nc	(nc-nc)

Male	0	1.8	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	4	1.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Ovary				
Female	0	1.3	nc	(nc-nc)
Pancreas				
Male	0	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Prostate				
Male	8	14.8	54.1	(23.3-106.7)
Stomach				
Male	0	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Testis				
Male	1	0.5	nc	(nc-nc)
Thyroid				
Male	0	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	2.6	nc	(nc-nc)
All Sites / Types				
Male	47	48.1	97.7	(71.8-130.0)
Female	39	41.2	94.6	(67.3-129.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

55

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	75	86.1	87.1	(68.5-109.2)	Male	41	44.7	91.8	(65.9-124.5)
Female	29	34.0	85.3	(57.1-122.6)	Female	37	38.6	95.8	(67.5-132.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	22	17.8	123.9	(77.6-187.6)	Male	10	12.0	83.1	(39.8-152.8)
Female	15	15.8	94.9	(53.1-156.5)	Female	8	10.6	75.8	(32.7-149.4)
Breast					Non-Hodgkin Lymphoma				
Male	1	2.6	nc	(nc-nc)	Male	44	44.3	99.4	(72.2-133.4)
Female	292	353.5	82.6	(73.4-92.6)	Female	32	42.7	75.0	(51.3-105.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	23	17.0	135.4	(85.8-203.1)	Male	47	33.1	141.9	(104.3-188.7)
Colon / Rectum					Female	20	17.3	115.9	(70.8-179.1)
Male	132	133.0	99.3	(83.1-117.7)	Ovary				
Female	120	139.1	86.3	(71.5-103.2)	Female	31	36.4	85.1	(57.8-120.8)
Esophagus					Pancreas				
Male	26	20.9	124.5	(81.3-182.4)	Male	26	24.7	105.1	(68.7-154.0)
Female	13	6.8	191.1	(101.6-326.7)	Female	29	28.8	100.6	(67.4-144.5)
Hodgkin Lymphoma					Prostate				
Male	7	8.1	86.3	(34.6-177.8)	Male	330	350.3	94.2	(84.3-104.9)
Female	5	7.3	68.5	(22.1-159.9)					

Kidney & Renal Pelvis					Stomach				
Male	29	34.6	83.9	(56.2-120.5)	Male	25	22.7	110.1	(71.2-162.5)
Female	20	24.2	82.7	(50.5-127.7)	Female	20	14.9	134.4	(82.1-207.6)
Larynx					Testis				
Male	15	15.5	96.6	(54.0-159.4)	Male	12	14.4	83.3	(43.0-145.6)
Female	6	4.3	139.8	(51.0-304.2)					
Leukemia					Thyroid				
Male	37	27.6	133.9	(94.3-184.6)	Male	7	8.8	79.1	(31.7-163.0)
Female	25	24.5	102.0	(66.0-150.5)	Female	35	30.0	116.6	(81.2-162.1)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	19	16.0	118.7	(71.4-185.4)					
Female	5	6.6	75.6	(24.4-176.4)	Female	62	69.4	89.3	(68.5-114.5)
Lung and Bronchus					All Sites / Types				
Male	189	168.2	112.4	(96.9-129.6)	Male	1196	1162.2	102.9	(97.2-108.9)
Female	174	154.8	112.4	(96.3-130.4)	Female	1093	1162.4	94.0	(88.5-99.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

56
Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	3.5	144.2	(46.5-336.5)	Male	0	1.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)

Breast	Female	1	0.6	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)
Cervix Uteri	Female	17	13.3	127.5	(74.2-204.2)
Colon / Rectum	Female	2	0.6	nc	(nc-nc)
	Male	5	5.3	93.7	(30.2-218.6)
Esophagus	Female	4	5.1	nc	(nc-nc)
	Male	4	0.8	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.2	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.2	nc	(nc-nc)
	Male	2	1.4	nc	(nc-nc)
Larynx	Female	0	0.9	nc	(nc-nc)
	Male	2	0.6	nc	(nc-nc)
Leukemia	Female	0	0.2	nc	(nc-nc)
	Male	1	1.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	1	0.9	nc	(nc-nc)
	Male	1	0.6	nc	(nc-nc)
Lung and Bronchus	Female	1	0.2	nc	(nc-nc)

Non-Hodgkin Lymphoma	Female	0	0.4	nc	(nc-nc)
	Male	2	1.7	nc	(nc-nc)
Oral Cavity & Pharynx	Female	2	1.6	nc	(nc-nc)
	Male	1	1.3	nc	(nc-nc)
Ovary	Female	0	0.6	nc	(nc-nc)
Pancreas	Female	2	1.4	nc	(nc-nc)
	Male	0	1.0	nc	(nc-nc)
Prostate	Female	1	1.1	nc	(nc-nc)
	Male	13	14.1	92.5	(49.2-158.2)
Stomach	Male	3	0.9	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)
Testis	Male	1	0.5	nc	(nc-nc)
Thyroid	Male	0	0.3	nc	(nc-nc)
	Female	2	1.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					
	Female	1	2.6	nc	(nc-nc)
All Sites / Types					

Male	10	6.8	146.5	(70.1-269.4)
Female	9	6.0	150.5	(68.7-285.7)

Male	53	46.4	114.3	(85.6-149.5)
Female	48	43.2	111.2	(82.0-147.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

57
Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	52	53.9	96.4	(72.0-126.5)	Male	35	28.4	123.4	(85.9-171.6)
Female	24	23.7	101.5	(65.0-151.0)	Female	35	27.8	126.1	(87.8-175.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	14	10.7	130.4	(71.2-218.8)	Male	4	7.5	nc	(nc-nc)
Female	11	10.5	104.4	(52.0-186.7)	Female	10	7.3	137.0	(65.6-252.0)
Breast					Non-Hodgkin Lymphoma				
Male	3	1.6	nc	(nc-nc)	Male	44	27.9	157.7	(114.6-211.7)
Female	271	242.7	111.6	(98.7-125.8)	Female	33	29.6	111.6	(76.8-156.7)
Cervix Uteri					Oral Cavity & Pharynx				
Female	8	12.1	65.8	(28.4-129.7)	Male	17	20.7	82.0	(47.7-131.2)
Colon / Rectum					Female	13	12.0	108.4	(57.7-185.4)
Male	67	83.4	80.3	(62.2-102.0)	Ovary				
Female	95	98.6	96.3	(77.9-117.7)	Female	31	25.3	122.8	(83.4-174.2)
Esophagus					Pancreas				
Male	11	13.0	84.4	(42.1-150.9)	Male	14	15.5	90.3	(49.4-151.6)
Female	2	4.8	nc	(nc-nc)	Female	18	20.4	88.3	(52.3-139.5)

Hodgkin Lymphoma					Prostate				
Male	5	5.4	92.5	(29.8-216.0)	Male	223	216.5	103.0	(89.9-117.4)
Female	9	5.4	166.7	(76.1-316.5)					
Kidney & Renal Pelvis					Stomach				
Male	25	21.4	116.6	(75.4-172.1)	Male	11	14.4	76.6	(38.2-137.0)
Female	18	16.4	110.1	(65.2-174.0)	Female	15	10.9	138.2	(77.3-227.9)
Larynx					Testis				
Male	7	9.6	72.6	(29.1-149.5)	Male	10	10.2	98.2	(47.0-180.6)
Female	2	2.8	nc	(nc-nc)					
Leukemia					Thyroid				
Male	22	16.8	131.1	(82.1-198.5)	Male	13	5.7	226.4	(120.4-387.2)
Female	15	16.7	89.9	(50.3-148.3)	Female	37	22.1	167.3	(117.8-230.6)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	5	9.9	50.3	(16.2-117.3)					
Female	5	4.7	107.2	(34.5-250.1)	Female	59	47.1	125.3	(95.4-161.7)
Lung and Bronchus					All Sites / Types				
Male	62	104.3	59.5	(45.6-76.2)	Male	700	725.3	96.5	(89.5-103.9)
Female	82	103.9	78.9	(62.8-97.9)	Female	840	805.5	104.3	(97.3-111.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

58
Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)

Brain and Other Nervous System	Female	0	0.7	nc	(nc-nc)
	Male	0	0.4	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)
Breast	Male	0	0.1	nc	(nc-nc)
	Female	7	8.4	83.3	(33.4-171.6)
Cervix Uteri	Female	0	0.4	nc	(nc-nc)
	Male	3	3.5	nc	(nc-nc)
	Female	3	3.0	nc	(nc-nc)
Colon / Rectum	Male	1	0.6	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Esophagus	Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma	Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis	Male	0	0.9	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)
Larynx	Male	2	0.4	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Leukemia	Male	1	0.7	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					

Multiple Myeloma	Female	1	0.9	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
	Female	1	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma	Male	2	1.1	nc	(nc-nc)
	Female	0	0.9	nc	(nc-nc)
Oral Cavity & Pharynx	Male	1	0.9	nc	(nc-nc)
	Female	1	0.4	nc	(nc-nc)
Ovary	Female	0	0.8	nc	(nc-nc)
	Male	0	0.6	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)
Pancreas	Male	4	9.2	nc	(nc-nc)
Prostate	Male	0	0.6	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)
Stomach	Male	0	0.6	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)
Testis	Male	1	0.3	nc	(nc-nc)
Thyroid	Male	0	0.2	nc	(nc-nc)
	Female	0	0.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					

Male	0	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	2	4.4	nc	(nc-nc)	Male	20	30.1	66.4	(40.5-102.5)
Female	3	3.5	nc	(nc-nc)	Female	22	26.4	83.4	(52.2-126.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

59

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	34	24.3	139.7	(96.8-195.3)	Male	18	13.0	138.4	(82.0-218.7)
Female	7	8.7	80.8	(32.4-166.5)	Female	12	10.4	115.4	(59.6-201.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	8	5.1	157.9	(68.0-311.2)	Male	1	3.5	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.8	nc	(nc-nc)	Male	14	12.6	110.8	(60.5-185.9)
Female	102	98.4	103.6	(84.5-125.8)	Female	12	11.0	109.0	(56.3-190.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	4.6	nc	(nc-nc)	Male	9	10.1	89.1	(40.6-169.1)
					Female	6	4.7	127.7	(46.6-278.0)
Colon / Rectum					Ovary				
Male	32	38.1	84.1	(57.5-118.7)					
Female	32	33.5	95.7	(65.4-135.0)	Female	3	9.9	nc	(nc-nc)

Esophagus						Pancreas					
Male	6	6.3	94.6	(34.6-206.0)		Male	5	7.1	70.4	(22.7-164.3)	
Female	4	1.7	nc	(nc-nc)		Female	8	7.0	114.3	(49.2-225.2)	
Hodgkin Lymphoma						Prostate					
Male	3	2.2	nc	(nc-nc)		Male	115	111.9	102.8	(84.9-123.4)	
Female	2	1.8	nc	(nc-nc)							
Kidney & Renal Pelvis						Stomach					
Male	8	10.4	76.7	(33.0-151.2)		Male	7	6.3	110.4	(44.2-227.4)	
Female	3	6.6	nc	(nc-nc)		Female	3	3.4	nc	(nc-nc)	
Larynx						Testis					
Male	6	4.8	125.7	(45.9-273.6)		Male	4	3.9	nc	(nc-nc)	
Female	3	1.3	nc	(nc-nc)							
Leukemia						Thyroid					
Male	9	7.6	118.2	(53.9-224.4)		Male	4	2.7	nc	(nc-nc)	
Female	8	6.0	133.8	(57.6-263.6)		Female	11	8.1	135.6	(67.6-242.6)	
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
Male	6	4.8	125.7	(45.9-273.5)							
Female	0	1.6	nc	(nc-nc)		Female	15	20.2	74.4	(41.6-122.7)	
Lung and Bronchus						All Sites / Types					
Male	45	50.2	89.6	(65.3-119.8)		Male	357	346.8	102.9	(92.5-114.2)	
Female	40	42.5	94.0	(67.2-128.0)		Female	297	308.9	96.2	(85.5-107.7)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;